We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
- Authors
Farkouh, Michael E; Kirshner, Howard; Harrington, Robert A; Ruland, Sean; Verheugt, Freek W A; Schnitzer, Thomas J; Burmester, Gerd R; Mysler, Eduardo; Hochberg, Marc C; Doherty, Michael; Ehrsam, Elena; Gitton, Xavier; Krammer, Gerhard; Mellein, Bernhard; Gimona, Alberto; Matchaba, Patrice; Hawkey, Christopher J; Chesebro, James H; TARGET Study Group
- Abstract
The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen.
- Publication
Lancet (London, England), 2004, Vol 364, Issue 9435, p675
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(04)16894-3